Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection
- PMID: 37068020
- DOI: 10.1097/MJT.0000000000001629
Against Authority: The Bioethics of Ivermectin Use for COVID-19 Infection
Abstract
Background: The COVID-19 pandemic has brought new ethical challenges to both health care professionals and the general public. Among the ethical problems amplified during this period were the making of medical decisions to quickly introduce some drugs into therapeutic practice with unproven or insufficiently proven effects (such as ivermectin), the validity of drug testing, and the allocation of limited resources.
Fields of uncertainty: The COVID-19 pandemic brought to the attention of the entire scientific world a new problem, which exceeded the guidelines and rules known until then. Out of the desire to quickly solve this medical problem, a series of measures were taken, however not sufficiently validated in scientific terms; the recommendations regarding the use of drugs known for their properties to treat a greater number of conditions, such as ivermectin, was tried.
Data sources: A narrative review of the specialized literature was carried out using keywords such as COVID-19, ivermectin, ethics, and off-label medication from Scopus and Google Scholar but also of official documents developed at the international level (World Health Organization).
Ethics and therapeutic advances: The off-label use of ivermectin alone or in combination with other medications during COVID pandemic raised problems related to the demonstration of its effectiveness, but also to ethics, starting from the expectations that both the medical staff and the population had of it. Ivermectin therapy was also evaluated by analyzing the behavior of ivermectin based on ethical principles (nonmaleficence, beneficence, and respect for one's autonomy) or on justice. Even in times of pandemic, exceptionalism must not triumph, and finding an effective treatment must be done through studies that respect ethical standard.
Conclusions: The failures or rather lack of success in decision making during the pandemic showed that alongside scientific knowledge and the development of health policies, it is necessary to constantly evaluate the measures and decisions from an ethical point of view, and the prevention of slippages and abuses is not only necessary but even mandatory.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors have no conflicts of interest to declare.
Similar articles
-
Ivermectin and the Integrity of Healthcare Evidence During COVID-19.Front Public Health. 2022 Mar 1;10:788972. doi: 10.3389/fpubh.2022.788972. eCollection 2022. Front Public Health. 2022. PMID: 35299698 Free PMC article. Review.
-
Challenges for Medical Students in Applying Ethical Principles to Allocate Life-Saving Medical Devices During the COVID-19 Pandemic: Content Analysis.JMIR Med Educ. 2024 Jan 5;10:e52711. doi: 10.2196/52711. JMIR Med Educ. 2024. PMID: 38050366 Free PMC article.
-
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1. Trials. 2020. PMID: 33234158 Free PMC article. Clinical Trial.
-
Utilitarian Principlism as a Framework for Crisis Healthcare Ethics.HEC Forum. 2021 Jun;33(1-2):45-60. doi: 10.1007/s10730-020-09431-7. Epub 2021 Jan 15. HEC Forum. 2021. PMID: 33449232 Free PMC article.
-
Reimplantation of Implantable Cardiac Devices-An Ethical Controversy?Am J Ther. 2023 Jul-Aug 01;30(4):e353-e359. doi: 10.1097/MJT.0000000000001646. Epub 2023 Jun 7. Am J Ther. 2023. PMID: 37285587 Review.
References
-
- Woolhouse M, Scott F, Hudson Z, et al. Human viruses: discovery and emergence. Philos Trans R Soc B Biol Sci. 2012;367:2864–2871.
-
- Gorbalenya AE, Baker SC, Baric RS, et al. The species severe acute respiratory syndrome - related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536–544.
-
- Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574.
-
- Zhong NS, Zheng BJ, Li YM, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003. Lancet. 2003;362:1353–1358.
-
- World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Available at: https://covid19.who.int/data . Accessed January 10, 2023.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials